Skip to main content
Premium Trial:

Request an Annual Quote

Paul Selvin, Daniel O’Day, Michael Onuscheck, Christophe Lambert, Francesca Demichelis

BioNanomatrix has appointed biophysicist Paul Selvin to its scientific advisory board, the firm said last week. Selvin is a professor of physics and biophysics at the University of Illinois at Urbana-Champaign.

The California Healthcare Institute said last week that it has elected Daniel O’Day and Michael Onuscheck to its board of directors.
O’Day is currently president and CEO at Roche Molecular Diagnostics in Pleasanton, Calif. Onuscheck is president of the neuromodulation division at Boston Scientific.
CHI is a non-profit public-policy research organization representing California’s academic institutions, and biotechnology, medical device, diagnostics, and pharmaceutical firms.

Christophe Lambert, CEO of software firm Golden Helix, will co-chair the Copy Number Variation Data Analysis Team within the Microarray Quality Control project’s Genome-Wide Association Working Group, Golden Helix said last week.
Lambert will join co-chair Francesca Demichelis of the Institute for Computational Biomedicine at Weill Cornell Medical College.
The CNV Data Analysis Team now has over 50 members and aims to identify the sources of variation in results of analysis of copy number data on whole-genome microarrays.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.